Revises provisions relating to testing for sexually transmitted diseases. (BDR 40-745)
AB 360 revises Nevada’s requirements for syphilis screening during pregnancy and at certain health care encounters. The bill expands who must perform the examination for syphilis to include physician assistants and advanced practice registered nurses, not just physicians, when they are attending a pregnant woman during gestation. It also changes testing procedures for non-hospital medical facilities and hospital emergency departments or labor and delivery units by requiring testing of pregnant women who have not had prenatal screening, regardless of the reason for the visit, unless the woman refuses. In those circumstances, the bill directs facilities to use a rapid or point-of-care test instead of a standard serological test when timely lab results are not likely to be available before discharge, and it requires documentation of any refusal.
The bill also requires covered facilities to adopt policies to ensure compliance with the new screening rules and with applicable American College of Obstetricians and Gynecologists recommendations, so long as those recommendations do not conflict with state law. It creates an exemption for certain rural clinics owned, operated, or administered by state or local governmental entities from some of the facility-based testing and policy requirements. In addition, the bill authorizes the Division of Public and Behavioral Health to discipline licensed medical facilities that violate the new requirements, including through existing licensing enforcement tools such as denial, suspension, revocation, or administrative penalties.
AB 360 further amends Medicaid law to require reimbursement for rapid or point-of-care syphilis testing performed under the bill’s conditions, and it directs that such reimbursement be made separately from reimbursement for other prenatal care, to the extent federal financial participation is available. The bill also updates the list of sexually transmitted disease services covered under Medicaid to expressly include syphilis screening for pregnant women under the revised statute. The act takes effect immediately for rulemaking and administrative preparation, with the substantive provisions becoming effective on January 1, 2026.
The overall sentiment appears strongly supportive and noncontroversial. The bill passed the Assembly 42-0 and the Senate 21-0, indicating unanimous approval in both chambers. No committee transcript was provided, but the voting record suggests broad agreement with the bill’s public health purpose of improving early detection and treatment of syphilis in pregnancy.
The main policy issues embedded in the bill are operational rather than ideological: how to ensure timely testing in emergency and non-hospital settings, when to use rapid tests versus standard serological tests, and how to balance compliance obligations with facility capacity, especially in rural areas. The rural clinic exemption and the requirement to document refusals may reflect concerns about implementation burden, patient autonomy, and access in underserved communities. The Medicaid reimbursement changes also suggest an effort to reduce financial barriers for providers adopting rapid testing.
AB 360 amends NRS 442.010, 449.160, 449.163, and 422.27173 to expand pregnancy-related syphilis screening requirements, authorize enforcement against noncompliant facilities, and require Medicaid coverage and separate reimbursement for rapid or point-of-care syphilis testing when used under the bill’s conditions. It affects physicians, physician assistants, advanced practice registered nurses, non-hospital medical facilities, hospital emergency departments and labor and delivery units, Medicaid, and the Division of Public and Behavioral Health. The bill also creates a limited exemption for certain government-operated rural clinics and requires facilities to adopt compliance policies and document refusals.
The bill’s sentiment is strongly favorable. It received unanimous final passage in both the Assembly and Senate, with no recorded opposition in either chamber. The available record suggests broad bipartisan or cross-party agreement that the measure addresses a public health concern and improves prenatal screening and treatment pathways.
No major opposition is reflected in the voting record or provided transcripts. The likely points of implementation concern are the new rapid-testing mandate in some settings, the requirement that facilities create compliance policies, the documentation of refusals, and the exemption for certain rural clinics. Those provisions suggest the bill attempts to balance stronger screening requirements with operational flexibility, especially where immediate lab results or staffing may be limited.